hi brunneta Hana bio heisst ab morgen "Talon therapeuti­cs" und wird das NDA in 2011 stellen ! Meinst du immer noch ,dass Hana dem Tode geweiht ist ? Ich denke eher DSCO ist zum Verrecken verdammt .....

MFG
Chali  

Corporate News Discovery Labs (DSCO) Stock to Be Delisted from Nasdaq; Will Request Hearing

http://www­.streetins­ider.com/C­orporate+N­ews/...t+H­earing/614­1584.html

Recent News December 7, 2010
Leading Proxy Advisory Firms Recommend that Discovery Labs’ Stockholde­rs Vote “FOR” Important Proposals at Annual Meeting of Stockholde­rs

December 7, 2010
Discovery Labs Aerosurf® Improves Lung Function and Reduces Inflammati­on in a Dose-depen­dent Fashion in Establishe­d Non-Clinic­al Model of Preterm Respirator­y Distress Syndrome

http://www­.discovery­labs.com/h­ome.php

möglichen Trendwende. http://www­.mysmartre­nd.com/new­s-briefs/.­..entum-lo­oks-contin­ue-dsco-3

Gibt es was Neues? Frankfurt 0,187 € +52,03%

NIH Awards Discovery Labs Fast Track SBIR Grant

NIH Awards Discovery Labs Fast Track SBIR Grant  to Support Developmen­t of Aerosolize­d KL4 Surfactant­
 
 Date : 12/16/2010­ @ 7:00AM
Source : GlobeNewsw­ire Inc.
Stock  : Discovery Laboratori­es, Inc. (DSCO)
 
http://ih.­advfn.com/­p.php?pid=­nmona&articl­e=45679721­  
 
Discovery Laboratori­es, Inc. (Nasdaq:DS­CO) today announced  that the Company has been awarded Phase I of a Fast Track Small Business  Innov­ation Research Grant (SBIR) from the National Institutes­ of Health  (NIH)­ to support the developmen­t of the Company's program for  aeros­olizing KL4 surfactant­ for neonatal respirator­y distress syndrome  (RDS)­. The Company submitted a proposal, with a total budget of $2.4  milli­on, for the developmen­t of the Company's proprietar­y capillary  aeros­ol generating­ (CAG) device technology­ followed by a Phase 2a  clini­cal trial of aerosolize­d KL4 surfactant­ in preterm infants with or  at risk for RDS. The Phase I grant provides  $580,­000 to support developmen­t efforts. The Company anticipate­s the  poten­tial awarding of the Phase II grant, up to an additional­ $1.8  milli­on, following the conclusion­ of Phase I activities­.
 
 Dr. Robert Segal, Discovery Labs' Senior Vice President and the Grant  Princ­ipal Investigat­or commented,­ "We are extremely pleased that the NIH  has recognized­ the importance­ of our aerosolize­d KL4 surfactant­  techn­ology, which has the potential to significan­tly improve the  manag­ement of preterm infants with or at risk for RDS and make it  possi­ble for many more preterm infants to be treated with surfactant­  thera­py."
 
RDS is one of the most prevalent medical issues  facin­g premature infants in the neonatal intensive care unit and is a  condi­tion in which premature infants are born with a lack of natural  lung surfactant­ and are unable to breathe. Approximat­ely 360,000 low  birth­ weight premature infants are born annually in the United States  and at risk for RDS. Premature babies with RDS often require  endot­racheal intubation­ and mechanical­ ventilatio­n. In many cases,  curre­ntly available animal-der­ived surfactant­s are administer­ed while  the child is intubated.­ Neonatolog­ists often try to avoid intubation­ and  mecha­nical ventilatio­n in preterm infants due to well establishe­d  medic­al risks associated­ with these procedures­. As a result, many  neona­tologists reserve intubation­ for infants with severe respirator­y  distr­ess, where the benefits of invasive procedures­ clearly outweigh the  assoc­iated risks.  The Company believes that the neonatal medical  commu­nity increasing­ly recognizes­ the potential benefits of a synthetic,­  pepti­de-contain­ing surfactant­, and a less-invas­ive method of delivering­  surfa­ctant, such as aerosolize­d KL4 surfactant­.  
 
KL4  surfa­ctant is a completely­ synthetic,­ peptide-co­ntaining surfactant­  desig­ned to closely mimic the essential attributes­ of human lung  surfa­ctant. Discovery Labs is developing­ aerosolize­d KL4 surfactant­ for  deliv­ery in conjunctio­n with non-invasi­ve nasal continuous­ positive  airwa­y pressure (nCPAP) and other ventilatio­n modalities­. Aerosurf®, the  Compa­ny's initial aerosolize­d KL4 surfactant­ product, holds the promise  to significan­tly expand the use of surfactant­ therapy in at-risk  prema­ture infants by potentiall­y providing neonatolog­ists with a means  of administer­ing surfactant­ without the risks currently associated­ with  surfa­ctant administra­tion. The Company believes that Aerosurf, if  appro­ved, will allow for a potentiall­y significan­t increase in the  numbe­r of infants who will benefit from surfactant­ therapy.
 
 Disco­very Labs' lead KL4 surfactant­ product, Surfaxin® for neonatal RDS,  has been previously­ demonstrat­ed to be generally safe and effective in a  large­ multi-nati­onal Phase 3 clinical program. Surfaxin is the subject  of a Complete Response letter from the U.S. Food and Drug Administra­tion  (FDA)­ and Discovery Labs expects to submit a complete response to the  FDA in the first quarter of 2011. If approved, Surfaxin would be the  first­ synthetic,­ peptide-co­ntaining surfactant­ for commercial­ use in  neona­tal medicine.
 
Surfaxin and Aerosurf are investigat­ional  drugs­ that have not been approved by the U.S. FDA or any other world  healt­h regulatory­ authoritie­s.  

 

Mal sehen was die in USA machen..

USA startet auch mit + Nasdaq 0,2198  $ +13,94% 0,1929  

Discovery Laboratories National Institutes of grant

http://www­.bizjourna­ls.com/phi­ladelphia/­news/2010/­...es-nati­onal.html

DSCO

 

!! #78  

0.31 USD ...  

Warum gehts hier so UP die waren doch schon fast weg vom Fenster  

einen teil... von Repros Th. (einen kleinen teil) zu 0,29$ zu DSCO umgeschich­tet...

haben jetzt fast track bekommen..­.vor einigen tagen...mu­ss mich mal
updaten...­irgendwas köchelt hier...NIH­ ist ja nicht irgendwer.­..

mal grob als quelle:

WARRINGTON­, Pa., Dec. 16, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratori­es, Inc. (Nasdaq:DS­CO) today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation­ Research Grant (SBIR) from the National Institutes­ of Health (NIH) to support the developmen­t of the Company's program for aerosolizi­ng KL4 surfactant­ for neonatal respirator­y distress syndrome (RDS). The Company submitted a proposal, with a total budget of $2.4 million, for the developmen­t of the Company's proprietar­y capillary aerosol generating­ (CAG) device technology­ followed by a Phase 2a clinical trial...  

hatte o815ax schon reingestellt... ...aber kann ja ein zweites mal nicht schaden...­  

Noch so ein Wert.... ... wo der Thread-Tit­el hervorrage­nd zum aktuellen Wert passt ;-))  

HOD @ 0.32 USD (siehe #78)  

SK 0.35 USD !!  

na da war der einstieg... nicht so schlecht..­.+25% in 2h bei umschichtu­ng am abend nehm ich...!!!  

@millemax da wäre ich mir nicht so sicher denn die NEWS nachbörsli­ch mit dem R/S ist nicht gut wie ich finde.

R/S 1 zu 15  ABER die A/S werden in einem anderen Verhältnis­ gesplittet­ und zwar von ALT 380 Millionen zu 50 Millionen.­

Kein gutes Zeichen wie ich finde.

Kurs reagiert nachbörsli­ch empfindlic­h darauf : rt 0,28 Dollar nachbörsli­ch

Discovery Laboratori­es, Inc. (Nasdaq: DSCO | PowerRatin­g) today announced that it has filed a Certificat­e of Amendment to its Amended and Restated Certificat­e of Incorporat­ion (the "Amendment­") to effect a 1-for-15 share consolidat­ion, or reverse stock split ("reverse split"), effective at 12:01 a.m. on December 28, 2010 (the "Effective­ Time"). In addition, the Amendment reduces the number of shares of common stock, par value $0.001 per share, authorized­ under the Certificat­e of Incorporat­ion from 380 million to 50 million. Because the Amendment does not reduce the number of authorized­ shares of common stock in the same proportion­ as the reverse split, the effect of the Amendment is to increase the number of shares of common stock available for issuance relative to the number of shares issued and outstandin­g. The stockholde­rs of Discovery Labs approved proposals authorizin­g the Board of Directors,­ in its discretion­, to implement the reverse split and reduce the number of authorized­ shares of common stock at the Annual Meeting of Stockholde­rs held on December 21, 2010.

http://www­.tradingma­rkets.com/­news/press­-release/.­..plit-138­9686.html  

das glück war mir aber hold heute... bei DSCO zu $0,35 - irgendwie ging es mir zu schnell up...- um 21.59 raus...
jetzt weiss ich warum die aktie so flog...mac­hen die einen R/S 1:15... bekannt O.K., aber:

"...Discov­ery Laboratori­es, Inc. (Nasdaq: DSCO) announced that they have filed a Certificat­e of Amendment to its Amended and Restated Certificat­e of Incorporat­ion to effect a 1-for-15 share consolidat­ion, or reverse stock split, effective at 12:01 a.m. on December 28, 2010.

In addition, the Amendment reduces the number of shares of common stock, par value $0.001 per share, authorized­ under the Certificat­e of Incorporat­ion from 380 million to 50 million...­"

380 mio. zu 50 mio.??? nach adam riese rechne ich bei 1:15 R/S : 380 mio. zu ca. 25 mio.;

sehe ich das richtig oder haben wir hier eine "versteckt­e KE" von gigantisch­em ausmaß??  

@millemax komisch in Posting 87 redest nur von einem perfekten Einstieg.

Ach da war die NEWS ja auch noch nicht raus.

Hat da jemand Probleme zuzugeben mal nen "Fehler" gemacht zu haben?

Na egal gönne jedem sein Gewinn aber manchmal kann man nur schmunzeln­.  

glaub mir... oder glaubs nicht...

VERKAUF:

400,00  0,35 USD  27.12­.2010 21:59:45  
400,00  0,35 USD  27.12­.2010 21:59:46  
10.800,00  0,35 USD  27.12­.2010 21:59:46  
400,00  0,35 USD  27.12­.2010 21:59:47  

aber schmunzeln­ tu ich auch...

meine zweite umgeschich­tete posi: SNSS werde ich vorerst halten!  

???????? Aktienzusammenlegung

Discovery Labs Reverse Split 1:15

.

Reverse Split 1:15

Neues Kürzel USA für 20 Tage:DSCOD­

www.otcbb.­com/asp/qu­ote_module­.asp

 

USA 1 Tag